Scaling up rAAV downstream processing from 2 L to 200 L scale: building a robust, scalable purification platform

Thursday 08:00 PDT / 11:00 EDT / 16:00 BST / 17:00 CEST

Sponsor

Scaling up rAAV downstream processing from 2 L to 200 L scale: building a robust, scalable purification platform

Reliable rAAV supply underpins the progression of gene therapies from development toward clinical and commercial manufacture. Yet scaling a downstream process from development to manufacturing scale often introduces new variability in recovery, purity, and capsid quality.

This webinar presents a real industrial case study on scaling a recombinant rAAV8 downstream process from 2 L development through 50 L pilot to 200 L engineering scale. Attendees will see quantitative recovery, purity, and quality data generated at each scale, demonstrating predictable performance from bench to engineering manufacturing.

Attend this webinar to:

See quantitative unit operation data, including depth filtration at >80% recovery, affinity capture at ≥80% vital genome recovery with <5% breakthrough, and anion exchange polishing reaching up to 80% full capsids.
Understand how the overall process delivered 7.9 × 10¹⁶ viral genomes at 200L scale with >30% overall recovery, while holding residual host-cell protein below 20 ng/mL.
Gain a practical framework for identifying and controlling critical unit operations, particularly AEX monolithic chromatography, to support future GMP and clinical manufacturing readiness.

Florian Leseigneur, PhD

Head of Downstream Process Development at DINAMIQS

Florian has over 10 years of experience in viral vector process development, with expertise in downstream process of lentiviral and AAV gene therapy products. He joined DINAMIQS as Head of Downstream Development in 2021. Prior to that, he served as a Senior Scientist at leading European organizations Cell & Gene Therapy Catapult and Celonic Group.

Florian holds a PharmD from Paris Descartes University and an MSc from Paris-Sud University. His PharmD residency provided broad exposure, including pharmacology and toxicology labs, radiopharmaceutical controls, and hospital-based preparation, quality control, and release of sterile injectables such as antibody-drug conjugates for clinical trials.

Teja Nusdorfer

Product Manager at Sartorius

Teja is a Product Manager for AAV and bacteriophage purification using CIM® monoliths at Sartorius BIA Separations. She has built a strong technical foundation in monolithic chromatography and AAV purification, working closely with customers to translate their process challenges into robust, CIM® monolith-based purification solutions from development through scale-up. Teja holds a master’s degree in biotechnology from the University of Ljubljana.

In 14 Days

You have registered for this webinar